DEXIS to Showcase Cutting-Edge Innovations at IDS 2025
QUAKERTOWN, PENNSYLVANIA / ACCESS Newswire / March 24, 2025 / DEXIS, the global leader in dental imaging technologies, is excited to announce its participation in the International Dental Show (IDS) 2025 in Cologne, Germany.
The company will showcase new technologies within the DEXIS digital ecosystem, an AI-powered platform that connects each step of the digital workflow, from diagnosis to delivery. The ecosystem combines AI, 2D & 3D imaging, intraoral scanning, diagnostics, and treatment planning to create one integrated solution that streamlines processes and boosts productivity.
"We're excited to give IDS attendees the very first look at some of our new technologies," says DEXIS President, Robert Befidi. "All of our innovations are designed to improve patient interactions and make dental practices more effective and efficient. We're eager to put our products into the hands of dental professionals and demonstrate the capabilities of our new technologies."
Among these innovations are some exciting updates to the DEXIS intraoral scanning portfolio. Visitors will get an exclusive first look at the company's all-new intraoral scanner under development, Imprevo. With a sleek new design, fully rebuilt hardware, and AI-powered algorithm, Imprevo will become the new high-performance flagship of the DEXIS IOS portfolio.
IS ScanFlow, the software that powers the DEXIS intraoral scanner line, will preview its newest version, IS ScanFlow 2.0, featuring a new Smile Visualizer tool. The tool will allow dental professionals to show patients a realistic preview of their smile before and after treatments, helping them to visualize and better understand treatment recommendations.
DEXIS will also unveil updates to the ORTHOPANTOMOGRAPH™ OP 3D™ EX, which will soon include cephalometric imaging capabilities. The new ceph modality, which features the company's patented ORTHOceph™ Plus design, will provide necessary protocols such as lateral and pediatric lateral projections, posterior-anterior projections and carpus imaging* - all with fast scan times and at a limited dose.
Additionally, the DEXIS 3D imaging portfolio will introduce an Automatic Dose Control feature for the ORTHOPANTOMOGRAPH™ OP 3D™ LX. The feature will measure patients' anatomy and automatically set exposure levels for optimal image quality and dose. Early adopters have reported positive feedback:
"The new Automatic Dose Control is one of the few things in life I don't have to question," says Dr. Katya Archambault of San Diego Health Center. "It offers both better and more consistent image quality. I could never argue with the results."
Also being showcased are new features within DTX Studio™ Clinic, the core software of the DEXIS digital ecosystem. Known for its comprehensive integration of all modalities of patient data, DTX Studio Clinic streamlines diagnostics, patient education, treatment planning, and surgical guide generation.
The software's new features include a suite of tools designed to streamline the implant treatment planning process. Users can now plan an implant treatment and generate an automated surgical template chairside in under 3 minutes. Additionally, the software introduces an Assisted Implant Planning module that automates initial implant positioning, and a Face Scan tool that integrates facial scans with 3D X-rays, further enhancing the planning process.
Attendees will also get the chance to preview new innovations, set to be released in future updates of DTX Studio Clinic. Among these innovations is a new, AI-driven endodontic capability, that will provide 3D visualizations of root canals, enhancing diagnostic accuracy and treatment efficiency. Additionally, updates to the focus areas detection tool will be showcased, enhancing the visualization of teeth in intraoral X-rays and detecting eight additional dental findings.
DTX Studio Clinic will also introduce a new Cloud-based solution that will allow clinicians to connect their practices and consolidate data in one place. This feature is designed to enhance collaboration and streamline workflows, ultimately improving practice efficiency and patient outcomes. These advancements showcase the future of dental technology, making DTX Studio Clinic an integral part of modern dentistry.
DEXIS invites all IDS attendees to visit Hall 11.2 K050 L069 to experience the innovations that DEXIS has to offer. Their team of experts will be ready to provide demonstrations and answer questions.
With more than 165,000 solutions in use around the world, DEXIS continues to set the standard for quality and reliability in dental imaging. For more information about DEXIS and its participation in IDS, please visit DEXIS @ IDS 2025.
About DEXIS
DEXIS is the global leader in dental imaging. We bring together the most trusted brands in 2D and 3D imaging, intraoral scanning solutions, and diagnostic software, in one connected and AI-powered ecosystem. Our innovative and award-winning technologies use smart simplicity to increase productivity and enhance diagnostic confidence. For more information, please visit DEXIS.com.
About Envista
Envista Holdings Corporation is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide array of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.
DXIS01006/Rev00
*Carpus is an optional imaging program
Contact Information
Maria Penaloza
Media & Content Strategy Manager
mariap@accessnewswire.com
Michelle Cabral
Senior Marketing Director, DEXIS
michelle.cabral@envistaco.com
SOURCE: Envista
View the original press release on ACCESS Newswire
Envista
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra to Supply Foster Medical Compounds Across the Americas15.7.2025 16:45:00 CEST | Press release
Following GEON's acquisition of Foster, LLC, this new agreement expands Formerra's healthcare polymer portfolio with life-saving medical compounds. ROMEOVILLE, IL / ACCESS Newswire / July 15, 2025 / Formerra, a leader in performance materials distribution, today announced an agreement with GEON® Performance Solutions that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in North America and South America. The agreement follows GEON's acquisition of Foster, LLC, and builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "This expanded partnership equips our customers with a broader set of proven medical-grade solutions while leveraging Formerra's technical guidance and robust supply-chain capabilities," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Foster's brand strength and GEON's investment momentum create powerful growth potential for these materials and our cust
FairWinds Migrates from .COM to .FAIRWINDS, Showcasing Leadership in Strategic Internet Addressing15.7.2025 16:00:00 CEST | Press release
WASHINGTON, DC / ACCESS Newswire / July 15, 2025 / FairWinds Partners, the world's leading domain name strategy consultancy, has completed the migration of its website from fairwindspartners.com to home.fairwinds. "This transition is more than a domain change. It reflects our belief in the future of .BRAND top-level domains," said FairWinds founder Josh Bourne. "Our move to .FAIRWINDS reinforces the strategic value that these top-level domains offer and our evolution from a pioneering domain name advisory firm to the trusted partner for global brands navigating the digital landscape via the address bar." Unlike second-level domains like google.com, top-level domains reside on the internet's root servers -- the foundation of the internet's naming system. .BRAND top-level domains are not publicly available and are used exclusively by the brand owner. ".BRAND top-level domains provide a powerful way to amplify, control, and secure a brand's digital presence while giving visitors visual pr
QorusDocs Reports 360% Increase in Customers Using AI to Manage Proposals, Acquires Shark Finesse to Build Unified AI-Powered Value and Proposal Platform15.7.2025 13:00:00 CEST | Press release
BELLEVUE, WA / ACCESS Newswire / July 15, 2025 / QorusDocs, an AI-powered proposal management software company that streamlines creation of pitches, proposals and request for proposal (RFP) responses, today announced that its customers' use of AI to manage proposals has grown 360% year over year, and that it has acquired Shark Finesse Ltd, a United Kingdom-based AI-powered customer value management software. "AI is completely transforming how business development teams win business, and QorusDocs is at the forefront," said Ray Meiring, CEO of QorusDocs. "The majority of our customers now rely on AI to manage proposals. We're at a pivotal moment, and with the acquisition of Shark Finesse, we're poised to deliver on companies' full revenue enablement journey, from proving value to winning the deal." QorusDocs Acquires Shark Finesse With Shark Finesse joining QorusDocs, the company's vision is to enable business development and proposal teams to prove value early in the revenue cycle, wit
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease15.7.2025 09:50:00 CEST | Press release
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).AATec Medical and Northway Biotech Announce Partnership Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-
IXOPAY Surges Past 500 Certified Adapters, Solidifies Leadership in Enterprise-Grade Payment Orchestration15.7.2025 06:00:00 CEST | Press release
With 200 PSPs and 300 payment methods, IXOPAY is unlocking faster global expansion, improved approval rates, and full-stack control for enterprise merchants. LEHI, UT / ACCESS Newswire / July 15, 2025 / As global commerce accelerates, enterprise merchants are hitting a wall - their legacy payment stacks weren't built for the scale, complexity, or speed modern commerce demands. To stay competitive, merchants need infrastructure that adapts across markets, providers, and payment methods without costly rewrites or vendor lock-in. IXOPAY, a global leader in enterprise-grade payment orchestration, is addressing that challenge head-on with the announcement it has reached 500 certified adapters, connecting 200 payment service providers (PSPs) and 300 payment methods through a single, vendor-agnostic API. Payment orchestration is rapidly emerging as vital infrastructure for modern payments, and its effectiveness depends on the scale and breadth of the adapter ecosystem. IXOPAY's industry-leadi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom